(Q48961678)

17 February 2018

title

The generalizability of antidepressant efficacy trials to routine psychiatric out-patient practice. (English)

1 reference

17 February 2018

1 reference

R van der Lem

1

1 reference

17 February 2018

N J A van der Wee

series ordinal

2

1 reference

17 February 2018

T van Veen

series ordinal

3

1 reference

17 February 2018

F G Zitman

series ordinal

4

1 reference

17 February 2018

language of work or name

English

0 references

publication date

16 November 2010

1 reference

17 February 2018

published in

Psychological Medicine

1 reference

17 February 2018

volume

41

1 reference

17 February 2018

issue

7

1 reference

17 February 2018

page(s)

1353-1363

1 reference

17 February 2018

Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Measuring depression: comparison and integration of three scales in the GENDEP study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Cognitive therapy vs medications in the treatment of moderate to severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

A reevaluation of the exclusion criteria used in antidepressant efficacy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Six months of treatment for depression: outcome and predictors of the course of illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Randomized controlled trials in psychiatry. Part II: their relationship to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Characteristics of insured and noninsured outpatients with depression in STAR(*)D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Cost-effectiveness of collaborative care including PST and an antidepressant treatment algorithm for the treatment of major depressive disorder in primary care; a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Depression rating scales can be related to each other by simple equations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

The STAR*D trial: the 300 lb gorilla is in the room, but does it block all the light?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Development of a Rating Scale for Primary Depressive Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Relevance of exclusion criteria in antidepressant clinical trials: a replication study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

A short form of the Dimensional Assessment of Personality Pathology-Basic Questionnaire (DAPP-BQ): the DAPP-SF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Review: a gentle introduction to imputation of missing values

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Patients Excluded From an Antidepressant Efficacy Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

Montgomery-Asberg severity gradations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

7 January 2021

A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

7 January 2021

Symptom severity and exclusion from antidepressant efficacy trials

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

7 January 2021

Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

7 January 2021

A comprehensive psychopathological rating scale

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

7 January 2021

Generalisability of results from randomised drug trials. A trial on antimanic treatment

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

7 January 2021

Reliability and validity of the Dutch Dimensional Assessment of Personality Pathology-Short Form (DAPP-SF), a shortened version of the DAPP-Basic Questionnaire

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

7 January 2021

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

7 January 2021

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

7 January 2021

Sequential treatment of mood and anxiety disorders.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

7 January 2021

Can mildly depressed outpatients with atypical depression benefit from antidepressants?

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

7 January 2021

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

7 January 2021

Dimensions of Personality Pathology

1 reference

https://api.crossref.org/works/10.1017%2FS0033291710002175

7 January 2021

10.1017/S0033291710002175

Identifiers

DOI

1 reference

17 February 2018

1 reference

17 February 2018